GC Biopharma Corp. (KRX:006280)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Manufacturing and Sales of Pharmaceuticals, Etc.	1.58T	1.44T	1.48T	-	1.43T
Manufacturing and Sales of Pharmaceuticals, Etc. Growth	9.72%	-2.94%	-	-	8.58%
Diagnosis and Analysis of Samples, Etc.	200.12B	213.76B	262.18B	-	99.64B
Diagnosis and Analysis of Samples, Etc. Growth	-6.38%	-18.47%	-	-	41.89%
Other	16.06B	18.50B	22.10B	-	19.33B
Other Growth	-13.17%	-16.29%	-	-	22.82%
Consolidation Adjustment	-117.27B	-46.49B	-57.45B	-	-42.08B
Energy Storage Device Manufacturing and Sales	-	-	-	1.54T	-
Profit and Loss from Discontinued Operations	-	-	-	-	-2.67B
Total	1.68T	1.63T	1.71T	1.54T	1.50T
Total Growth	3.27%	-4.95%	11.28%	2.24%	10.83%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Overseas	380.65B	272.87B	306.71B	39.46B	271.82B
Overseas Growth	39.50%	-11.03%	677.21%	-85.48%	18.54%
South Korea	1.42T	1.40T	1.46T	9.50B	1.28T
South Korea Growth	1.16%	-4.23%	15297.99%	-99.26%	8.82%
Consolidation	-117.27B	-46.49B	-57.45B	-	-42.08B
Discontinued Operations	-	-	-	-	-2.67B
Total	1.68T	1.63T	1.71T	48.96B	1.50T
Total Growth	3.27%	-4.95%	3395.47%	-96.75%	10.83%

Source: S&P Global Market Intelligence.